Summary
MDT Chart
Medtronic Afferaâ„¢ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients
One-year clinical trial data for the next-generation, investigational, Sphere-360â„¢ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-energy (RF/PF), focal Sphere-9â„¢ catheter demonstrates efficacy for linear ablation in persistent AFib Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting GALWAY, Ireland and SAN DIEGO , April 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Afferaâ„¢ family of technologies, including the next-generation Sphere-360â„¢ single-shot pulsed field ablation (PFA) catheter and the groundbreaking Sphere-9â„¢ combination mapping and dual-energy focal PFA catheter. Data were presented in High Impact Science Sessions at the Heart Rhythm Society 2025 Annual Meeting in San Diego; the Sphere-360 study was simultaneously published in the Heart Rhythm Journal.
2 Outstanding Dividend Stocks to Buy and Hold For 20 Years
Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold on through market volatility. In fact, it's still a great time to invest in companies that have excellent underlying businesses and attractive long-term prospects.
Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugoâ„¢ robotic-assisted surgery system
Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as a late-breaker at the American Urologic Association annual meeting Company confirms Hugo RAS system submission to the U.S. Food and Drug Administration GALWAY, Ireland and LAS VEGAS , April 26, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption (IDE) clinical study, the largest such study for robotic-assisted urologic surgery ever conducted, met both primary safety and effectiveness endpoints. The prospective, multi-center, single-arm IDE study included 137 patients who underwent urologic procedures using the Hugoâ„¢ robotic-assisted surgery (RAS) system.
Medtronic PLC Dividends
 MDT In 1 month Estimated | Quarterly | $0.7 Per Share |
| MDT 1 month ago Paid | Quarterly | $0.7 Per Share |
| MDT 4 months ago Paid | Quarterly | $0.7 Per Share |
| MDT 7 months ago Paid | Quarterly | $0.7 Per Share |
| MDT 10 months ago Paid | Quarterly | $0.7 Per Share |
| MDT 21 Mar 2024 Paid | Quarterly | $0.69 Per Share |
Medtronic PLC Earnings
| 22 May 2025 (23 Days) Date | | 1.58 Cons. EPS | - EPS |
| 18 Feb 2025 Date | | 1.36 Cons. EPS | 1.39 EPS |
| 19 Nov 2024 Date | | 1.25 Cons. EPS | 1.26 EPS |
| 20 Aug 2024 Date | | 1.2 Cons. EPS | 1.23 EPS |
| 23 May 2024 Date | | 1.45 Cons. EPS | 1.46 EPS |
| MDT In 1 month Estimated | Quarterly | $0.7 Per Share |
| MDT 1 month ago Paid | Quarterly | $0.7 Per Share |
| MDT 4 months ago Paid | Quarterly | $0.7 Per Share |
| MDT 7 months ago Paid | Quarterly | $0.7 Per Share |
| MDT 10 months ago Paid | Quarterly | $0.7 Per Share |
| MDT 21 Mar 2024 Paid | Quarterly | $0.69 Per Share |
| 22 May 2025 (23 Days) Date | | 1.58 Cons. EPS | - EPS |
| 18 Feb 2025 Date | | 1.36 Cons. EPS | 1.39 EPS |
| 19 Nov 2024 Date | | 1.25 Cons. EPS | 1.26 EPS |
| 20 Aug 2024 Date | | 1.2 Cons. EPS | 1.23 EPS |
| 23 May 2024 Date | | 1.45 Cons. EPS | 1.46 EPS |
Medtronic PLC (MDT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Medtronic PLC ever had a stock split?
Medtronic PLC Profile
| Medical Devices Industry | Healthcare Sector | Mr. Geoffrey Straub Martha CEO | NYSE Exchange | IE00BTN1Y115 ISIN |
| US Country | 95,000 Employees | 28 Mar 2025 Last Dividend | 27 Sep 1999 Last Split | 13 Jan 1978 IPO Date |
Overview
Medtronic plc is a global leader in medical technology, specializing in the development, manufacture, and sale of device-based medical therapies. Serving healthcare systems, physicians, clinicians, and patients around the world, the company is dedicated to alleviating pain, restoring health, and extending life for millions of people. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic operates across various medical domains through its diverse portfolio which includes cardiovascular, medical surgical, neuroscience, and diabetes treatments and technologies.
Products and Services
Medtronic’s comprehensive range of products and services is categorized into four primary segments:
- Cardiovascular Portfolio: This segment offers advanced device-based solutions for cardiac care, including:
- Implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices for heart rhythm management.
- Cardiac ablation products for treating atrial fibrillation.
- Insertable cardiac monitor systems for continuous heart monitoring.
- TYRX products, which involve antimicrobial envelopes for electronic implantable devices.
- Aortic valves, surgical valve replacement and repair products, transcatheter pulmonary valves, and endovascular stent grafts for structural heart disease treatment.
- Percutaneous coronary intervention products and angioplasty balloons for coronary artery disease treatment.
- Remote monitoring and patient-centered software for enhanced patient care.
- Medical Surgical Portfolio: This segment encompasses a broad array of surgical instruments and devices, including:
- Surgical stapling devices and vessel sealing instruments for precise surgical procedures.
- Wound closure products and electrosurgery products aimed at efficient surgical recovery.
- Surgical artificial intelligence and robotic-assisted surgery products for advanced surgical techniques.
- Hernia mechanical devices and mesh implants, along with other gynecology and lung health products.
- Minimally invasive gastrointestinal and hepatologic diagnostic and therapy tools, patient monitoring, airway management and ventilation therapies, and renal disease treatments.
- Neuroscience Portfolio: This segment delivers solutions for the central nervous system and supportive structures, including:
- Products for spinal, neuro, and orthopedic surgeries, pain management, and urology.
- Energy surgery instruments and image-guided surgery systems for enhanced surgical accuracy.
- Intra-operative imaging and robotic guidance systems for spine procedures.
- Therapies for brain vasculature conditions.
- Diabetes Operating Unit: Focused on diabetes management, this segment offers:
- Insulin pumps and consumables for continuous insulin delivery.
- Continuous glucose monitoring systems for real-time blood glucose tracking.
- Smart insulin pen systems and related consumables for modern diabetes care.
Contact Information
